NextCure, Inc.
About NextCure, Inc.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $22.4M
- Net income
- -$55.8M
- Total assets
- $50.2M
- Market cap
- $10.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $57.6M
- Operating income
- -$57.6M
- Income tax
- $0
- Net income
- -$55.8M
- EPS (basic)
- $-19.65
- EPS (diluted)
- $-19.65
Balance sheet
- Total assets
- $50.2M
- Current assets
- $43.7M
- Total liabilities
- $15.2M
- Current liabilities
- $10.6M
- Shareholders’ equity
- $34.9M
Cash flow
- Operating cash flow
- -$49.6M
- Investing cash flow
- $25.6M
- Financing cash flow
- $22.3M
- Net cash flow
- -$1.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $10.7M
- EPS (diluted)
- $-19.65
- Shares outstanding
- 3.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $55.8M in FY2020.
- Trading 80% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NextCure, Inc..
Write a review
News about NextCure, Inc.
News & sentiment via Polygon.io
